Skip to content
StockMarketAgent
Direct answer
NTES trades against a final fair-value range of $139.31-$218.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $139, high $219, with mid-point at $178.
Stock analysis

NTES fair value $139–$219

By StockMarketAgent.AI team· supervised by
Analizado: 2026-05-20Próxima actualización: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Mature compounder
View archive
Precio
$114.49
▲ +63.29 (+55.28%)
Valor razonable
$178
$139–$219
Calificación
Compra fuerte
confidence 82/100
Potencial alcista
+55.3%
upside to fair value
Margen de seguridad
$151.11
MoS level · 15%
Capitalización bursátil
$73.4B
P/E fwd 11.2
Respaldo en inglésES
Mostrando la fuente en inglés mientras traducimos
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.

§1 Resumen ejecutivo

  • Composite fair value $178 with high case $219.
  • Implied upside of 55.3% to fair value.
  • Moat 8/10 · confidence 82/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$178
Margin of safety
+35.6%
Confidence
82/100
Moat
8/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$114.49Price
Low $139.31
Mid $177.78
High $218.83

NTES trades against a final fair-value range of $139.31-$218.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Proprietary IP portfolio with 15+
    Proprietary IP portfolio with 15+ year lifecycle duration
  • Massive R&D scale supporting high-fidelity
    Massive R&D scale supporting high-fidelity production
  • Bull thesis
    Value: Trading at 11.2x fwd P/E vs 20x global peers

§2 Caso bajista

A bear-case stress test assuming a 500bps margin compression and 0% terminal growthTerminal growthThe perpetual growth rate assumed in the Gordon-growth terminal-value calculation. Capped below long-run nominal GDP (typically 2.5–3.0% for developed-market firms). resets fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. to $139.31. Even in this high-pessimism scenario, the massive net cash position ($40B+) provides a structural floor representing 55% of the current market capitalization.

Cómo puede fallar esta tesis

Regulatory Monetization Freeze

15%· Low

China introduces draconian caps on daily spending and loot box mechanics for legacy titles.

FV impact
40% decline
Trigger
6-12 months

Global Pipeline Failure

25%· Medium

High-budget international launches (Where Winds Meet) fail to gain traction, rendering global R&D sunk costs.

FV impact
15% decline
Trigger
18-24 months

Cash Seizure/Restricted Access

10%· Low

Geopolitical escalation leads to restrictions on offshore cash transfers or ADR de-listing.

FV impact
50% decline
Trigger
Immediate
Señales de alerta temprana a vigilar
MétricaActualUmbral de activación
Sustained quarterly ARPU decline in legacy titlesMonitorDeterioration versus the report thesis
Delay or cancellation of key 2026/27 global releasesMonitorDeterioration versus the report thesis
Reduction or suspension of established buyback programsMonitorDeterioration versus the report thesis
Operating margin compression below 28% thresholdMonitorDeterioration versus the report thesis
Resumption of aggressive regulatory finesMonitorDeterioration versus the report thesis

§3 Historial financiero

Cuenta de resultados — últimos seis períodos
ConceptoT−0T−1T−2T−3CAGR
Período2022-12-312023-12-312024-12-312025-12-31Trend
Ingresos$96.50B$103.47B$105.30B$112.63B+5.3%
Beneficio bruto$52.77B$63.06B$65.81B$72.40B+11.1%
Beneficio operativo$19.63B$27.71B$29.58B$35.83B+22.2%
Beneficio neto$20.34B$29.42B$29.70B$33.76B+18.4%
BPA (diluido)$30.85$45.25$45.95$52.40+19.3%
EBITDA$22.49B$30.76B$32.00B$38.08B+19.2%
I+D$15.04B$16.48B$17.52B$17.72B+5.6%
SG&A$18.10B$18.87B$18.70B$18.85B+1.4%

Puntuaciones de calidad

OCF / Beneficio neto
1.5×
>1 indica alta calidad de los beneficios
Umbral de calidad contable
Fail
Umbral ajustado por sector
ROIC
17.0%
Rentabilidad del capital invertido
Sección 3

Numbers analysis

Flujo de caja

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Asignación de capital

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Suscriptores individuales — desde §411 secciones más

Leer el análisis completo — 11 secciones más.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Informe completo para cada ticker cubierto
24 meses de archivo de calificaciones
Briefings de lista de seguimiento + alertas de cambio de calificación
Exportación PDF + DOCX en cualquier idioma
Comenzar prueba gratuita
Cancela cuando quieras.
FAQ

NTES — frequently asked questions

  1. Based on our latest analysis, NTES looks meaningfully undervalued. The current price is $114 versus a composite fair-value midpoint of $178 (range $139–$219), which implies roughly 55.3% upside to the midpoint.
Related coverage

Names readers of NTES also follow

Same archetype: mature-compounder